The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 22, 2020

Filed:

Sep. 27, 2016
Applicants:

National University Corporation Okayama University, Okayama-shi, Okayama, JP;

Momotaro-gene Inc., Okayama-shi, Okayama, JP;

Inventors:

Hiromi Kumon, Okayama, JP;

Rie Kinoshita, Okayama, JP;

Junichiro Futami, Okayama, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/574 (2006.01); C07K 16/18 (2006.01); C12N 5/12 (2006.01); C12N 15/02 (2006.01); G01N 33/53 (2006.01);
U.S. Cl.
CPC ...
G01N 33/574 (2013.01); C07K 16/18 (2013.01); C12N 5/12 (2013.01); C12N 15/02 (2013.01); G01N 33/53 (2013.01); C07K 2317/14 (2013.01);
Abstract

This invention provides an anti-REIC antibody that specifically recognizes a cancer-associated protein (REIC/Dkk-3) and enables monitoring of cancer treatment effects involving the use of the REIC/Dkk-3 gene or the REIC/Dkk-3 protein as a medicine. This invention also provides a method of diagnosis involving the use of such antibody. The method of diagnosis comprises a method of cancer detection comprising: measuring the REIC/Dkk-3 protein concentration in the biological sample obtained from a subject with the use of a first antibody or a functional fragment thereof that specifically recognizes the REIC/Dkk-3 protein having an active structure produced by a normal cell but does not recognize and bind to the REIC/Dkk-3 protein existing at a high level in the blood from a cancer patient or has low reactivity with the REIC/Dkk-3 protein existing at a high level in the blood from a cancer patient; and, when the REIC/Dkk-3 protein concentration in the biological sample obtained from the subject is lower than the REIC/Dkk-3 protein concentration in the biological sample from a healthy individual, determining that the subject is suffered from precancer or a neoplastic disease.


Find Patent Forward Citations

Loading…